Prasad Chandra
Internal Medicine · Cincinnati, OHNPI 1063468312
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 241 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Johnson & Johnson at 26.0% of the total. Reporting peaked in 2021 at $1,250 and has fallen 95.1% since, to $62 in 2023.
Across 241 payments — averaging $12.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$756
- Pfizer$348
- AbbVie$239
- Novo Nordisk$238
- Abbott$182
- Boehringer Ingelheim$145
- plus $999 from 18 others
What the payments were for
- Food & beverage$2,908100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 83 | $756 |
| Pfizer | 41 | $348 |
| AbbVie(2 entities) | 17 | $239 |
| Novo Nordisk | 15 | $238 |
| Abbott | 11 | $182 |
| Boehringer Ingelheim | 9 | $145 |
| AstraZeneca | 7 | $137 |
| Lilly USA, LLC | 9 | $127 |
| Novartis | 9 | $116 |
| Amgen(2 entities) | 8 | $113 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $90 |
| Amarin Pharma, Inc. | 4 | $73 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
| Esperion Therapeutics, Inc. | 3 | $43 |
| GSK | 3 | $41 |
| Bayer | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Merck | 2 | $30 |
| Shire North American Group Inc | 2 | $27 |
| Astellas Pharma US Inc | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Dexcom, Inc. | 1 | $18 |
| Si-bone, Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$2,908 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 12 | $252 |
| Simvastatin | 12 | $252 |
| Pantoprazole Sodium | 12 | $184 |
| Lovastatin | 12 | $181 |
| Donepezil Hcl | 12 | $145 |
| Omeprazole | 13 | $145 |
| Amlodipine Besylate | 12 | $100 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Cincinnati
- Lisa LarkinCincinnati$276K
- Vincent MartinCincinnati$261K
- Kay JohnsonCincinnati$184K
- Jason HatfieldCincinnati$72K
- Rajbir MinhasCincinnati$62K
- Hassan MalikAkron$1.7M
- Cyrus HarrisCleveland$726K
- Nina DeepWesterville$614K
- Necklall KhooblallAustintown$448K
- Daniel WeissMentor$406K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.